Elisa Garre-Garcia
Murcia, MU 30120, Spain
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 18 publications
Unlocking the predictive value of post-neoadjuvant immune biomarkers in breast cancer: neutrophil-to-lymphocyte ratio (NLR) and systemic immune-inflammation index (SII).
Journal: Breast cancer research and treatment
Published: November 02, 2025
Neoadjuvant Abemaciclib plus Letrozole vs. Chemotherapy in patients with HR+/HER2- Highly Proliferative Breast Cancer.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: June 30, 2025
Neoadjuvant Abemaciclib plus Letrozole Versus Chemotherapy in Patients with HR+/HER2- Highly Proliferative Breast Cancer.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: June 30, 2025
Deconstructing neutrophil to lymphocyte ratio (NLR) in early breast cancer: lack of prognostic utility and biological correlates across tumor subtypes.
Journal: Breast cancer research and treatment
Published: October 30, 2023
Clinical Meaning of Stromal Tumor Infiltrating Lymphocytes (sTIL) in Early Luminal B Breast Cancer.
Journal: Cancers
Published: April 14, 2023
A new prognostic model including immune biomarkers, genomic proliferation tumor markers (AURKA and MYBL2) and clinical-pathological features optimizes prognosis in neoadjuvant breast cancer patients.
Journal: Frontiers in oncology
Published: March 09, 2023
Palbociclib combined with endocrine therapy in heavily pretreated HR+/HER2- advanced breast cancer patients: Results from the compassionate use program in Spain (PALBOCOMP).
Journal: Breast (Edinburgh, Scotland)
Published: July 15, 2020
Clinical and biological impact of miR-18a expression in breast cancer after neoadjuvant chemotherapy.
Journal: Cellular oncology (Dordrecht, Netherlands)
Published: April 23, 2019
Neutrophil-lymphocyte ratio in metastatic breast cancer is not an independent predictor of survival, but depends on other variables.
Journal: Scientific reports
Published: February 28, 2019
Long-term response to first-line bevacizumab-based therapy in patients with metastatic breast cancer: results of the observational "LORENA" study.
Journal: OncoTargets and therapy
Published: October 02, 2018
Last Updated: 09/26/2026